Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 1125-1132

  Schneider, Jeffrey G ^a   Khalil, Danny N ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Breast cancer genetic signature; Oncotype DX recurrence score; Treatment decision making

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; ONCOTYPE DX RECURRENCE SCORE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84868215506     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2134-1     Document Type: Article

References (31)

1. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
2. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728
3. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734
4. Habel LA, Shak S, Jacobs MK et al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25
5. Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071
6. Esteva FJ, Sahin AA, Cristofanilli M et al (2005) Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11:3315-3319
7. Febbo PG, Ladanyi M, Aldape KD et al (2011) NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9(Suppl 5):S1-S32 Quiz S33
8. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312
9. Genomic Health Corporation (2011) Genomic health investor presentation (monograph online). http://investor.genomichealth.com/events.cfm. Accessed 24 Aug. 2011
10. Hornberger J, Chien R (2010) Meta-analysis of the decision impact of the 21-gene breast cancer recurrence score in clinical practice [abstract]. Cancer Res 70 (S24):S210
11. Lyman GH, Cosler LE, Kuderer NM et al (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018
12. Klang SH, Hammerman A, Liebermann N et al (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13:381-387
13. Lamond N W D, Skedgel C, Rayson D, Lethbridge L, Younis T (2012) Cost utility of the 21 gene recurrence score assay in nodenegative and node-positive breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-012-1989-5
14. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350
15. Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991
16. Fisher B, Dignam J, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682
17. Early Breast Cancer Clinical Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
18. Henry LR, Stojadinovic A, Swain SM et al (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99:319-323
19. Lo SS, Mumby PB, Norton J et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676
20. Asad J, Jacobson AF, Estabrook A et al (2008) Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196:527-529
21. Dowsett M, Cuzick J, Wale C et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in nodenegative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28:1829-1834
22. Dowsett M, Pineda S, Cuzick J (2010) Reply to M. Rossman et al. J Clin Oncol 28(31):e648
23. Oratz R, Paul D, Cohn AL et al (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3:182-186
24. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S (2011) The effects of oncotype DX recurrence scores on chemotherapy utilization in a multiinstitutional breast cancer cohort. Breast Cancer Res Treat 126:797-802. doi:10.1007/s10549-010-1329-6
25. Levine MN, Pritchard KI, Bramwell VH et al (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170
26. Munzone E, Curigliano G, Burstein HJ et al (2012) CMF revisited in the 21st century. Ann Oncol 23:305-311
27. Albain KS, Barlow WE, Ravdin PM et al (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine responsive, node-positive breast cancer: a phase 3 open label, randomised controlled trial. Lancet 374:2055-2063
28. Tang G, Cuzick J, Costantino JP et al (2011) Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365-4372
29. Nahta R, O'Regan RM (2012) Therapeutic implications of receptor signaling in HER2-psotive breast cancers. Breast Can Res Treat. doi:10.1007/s10549-012- 2067-8
30. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 62:233-247
31. Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K (2012) Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Breast Can Res Treat 133:145-159